Feminizing adrenocortical carcinoma with distant metastases: can surgery be considered? by Fancellu, Alessandro et al.
[page 30] [Clinics and Practice 2014; 4:651]
Feminizing adrenocortical carcinoma with distant metastases: can surgery be considered?
Alessandro Fancellu, Antonio Pinna,Alberto PorcuUnit of General Surgery 2, Departmentof Clinical and Experimental Medicine,University of Sassari, Italy
Abstract
Functioning adrenocortical carcinomas are
rare diseases with dismal prognosis. A 41-year-
old man presenting with gynecomastia had a
giant feminizing adrenocortical carcinoma at
stage IV. Although surgical resection was con-
troversial, we removed the primary tumor to
reduce the mass effects. He lived for 12
months with an acceptable quality of life.
Gynecomastia may be the first sign of feminiz-
ing adrenal malignancies. Surgery may ame-
liorate the quality of life in selected patients
with metastatic disease.
Introduction
While adrenal adenomas are quite frequent
in the general population, adrenal cortical car-
cinomas (ACCs) are rare malignancies affect-
ing only 2 per million per year in the world pop-
ulation.1,2 A bimodal age distribution has been
recognized, with first peak in childhood (<5
years of age) and second peak in 4th-5th decade
of life. Most of the ACCs are sporadic; however
they may also arise within the context of famil-
ial or hereditary diseases.2-4
Although different studies have been under-
taken in order to elucidate the molecular
pathogenesis of sporadic ACCs, to date none of
them has been proven to be completely
exhaustive.2,4 In particular, the genetic alter-
ations characteristic of the adenoma-carcino-
ma sequence has not clearly established. To
date, modification in three main molecular
patterns has been identified: insulin-like
growth factor (IGF)-2, the metabolic pathway
Wnt/β-catenin and TP53.4 ACCs can be either
functioning (i.e. producing hormones of the
adrenal cortex) or non-functioning. Adrenal
malignancies are more likely to be functioning
with respect to adenomas and can have differ-
ent clinical presentations, depending on the
type of hormonal secretion. In fact, patients
may have symptoms of hypercortisolism,
hyperaldosteronism, or sex hormone excess
(either virilization or feminization), although
mixed clinical features can be observed.1,5 
Feminizing ACCs, i.e. malignant adrenal
tumors causing features of estrogen excess,
are an extremely rare cause of abdominal
mass. 
We herein present a case of a young man
having a giant feminizing ACC with distant
metastases, which posed serious management
problems principally related to the burden of
the primary tumor. 
Case Report
A 41-year-old gentleman presented com-
plaining of a 6-month history of bilateral
gynecomastia without galactorrhea, and a sig-
nificant weight loss (8 kg in the last three
months). In the last two months he also
noticed abdominal and back pain, dyspepsia,
and some episodes of vomiting, bloating and
difficult passage of stools. The rest of his med-
ical history was not relevant and he was on no
medications. His family history revealed the
presence of a 37-year-old sister with an estab-
lished diagnosis of MEN1 (primary hyper-
parathyroidism, pancreatic gastrinoma, and
prolactinoma) with germline mutation 894-9
G→A, and a 50-year-old brother affected by an
adrenocorticotropic hormone (ACTH)-secret-
ing pituitary adenoma causing Cushing’s dis-
ease. As the patient was in good health before
the appearance of gynecomastia, he had previ-
ously refused to undergo laboratory and genet-
ic testing. Laboratory tests showed: i) extreme-
ly high estradiol plasma levels (E2>500),
together with undetectable gonadotropin levels
and low testosterone; ii) the likely coexistence
of Cushing’s disease (hypercortisolemia with
increased ACTH levels) (Table 1). In relation
to the latter, an overnight dexamethasone sup-
pression test (1 mg at 11.00 p.m.) was carried
out, which failed to show serum cortisol sup-
pression (19 μg/dL at 08.00 a.m.). On abdomi-
nal examination, a large, firm mass adherent
to the deep layers was palpable in the left quad-
rants. The total body computed tomographic
(CT) scan showed a large tumor of the left
adrenal (25 cm in its maximum diameter)
with colliquative areas infiltrating the left kid-
ney (Figure 1), left renal vein thrombosis, and
multiple liver and lung metastases. No pancre-
atic lesions were visible. Pelvic CT scan
revealed no abnormality, while breast and tes-
ticular ultrasound confirmed the presence of
gynecomastia and reduced testicular volume.
Neck ultrasound showed neither enlarged
parathyroid glands nor thyroid alterations.
Pituitary magnetic resonance imaging and
parathyroid sestamibi scan were also normal.
After a multidisciplinary discussion, it was
decided to operate on the patient to remove the
adrenal tumor, in an attempt to reduce the
symptoms related to the mass, principally pain
and recurrent subocclusive episodes. Before
the operation, a medication with ketoconazole
was started for hypercortisolemia; however,
replacement of ketaconazole with metyrapone
was necessary to normalize the cortisol levels.
The patient underwent an exploratory celioto-
my where a large encapsulated mass was
encountered, displacing the kidney inferiorly
and the distal pancreas and spleen superiorly.
The mass and the left kidney were resected en
bloc. On surgical exploration, the right adrenal
also appeared increased in size, thus a bilater-
al adrenalectomy was performed. On gross
pathology examination, the left adrenal tumor
(which included approximately half of the left
kidney, with diffusely infiltrated areas)
weighed 3.3 kg, and measured 27×17×12 cm
(Figure 2). The histological examination
revealed an ACC with oncocytic changes with a
Weiss score of 8 (Figure 3). Based on the his-
tological finding, the laboratory tests, and the
presence of distant metastases, we made the
diagnosis of feminizing adrenocortical carci-
noma at stage IV according to the American
Joint Committee on Cancer (AJCC) classifica-
tion. The right adrenal weighed 14 g and had
aspects of cortical hyperplasia. 
The postoperative course was uneventful,
and the patient was discharged on postopera-
tive day 12. He was given replacement therapy
with hydrocortisone, fludrocortisone, and
mitotane therapy without any important side
effects. Six months after surgery, laboratory
tests showed a normalization of cortisol and
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estrogens levels. Gynecomastia was markedly
improved, and a mild reduction of the size of
liver and lung metastasis was observed. He
went on to live 12 months with an acceptable
quality of life before dying from metastatic dis-
ease.
Discussion and Conclusions
Feminizing ACCs are very rare, accounting
for only 1-2% of all malignant neoplasms of
adrenal cortex.1 In 1994, Zayed reported fewer
than 100 cases described in male sex.6 Since
then, only a few cases have been added to the
literature. 
Clinical features related to steroid excess
occur in about 60% of ACCs, while feminizing
symptoms due to estrogen secretion are
extremely uncommon.1,5
The main presenting signs and symptoms of
feminizing ACC are gynecomastia, testicular
atrophy, decreased libido and impotence. In
line with other reported cases, gynecomastia
was the presenting symptom of ACC in our
patient.5,7 Gynecomastia recognizes various
causes, being most commonly due to medica-
tions, imbalance between testosterone/estro-
gen levels, kidney failure, cirrhosis, and much
more rarely to pituitary and adrenal tumors.7 It
has been suggested that feminizing symptoms
can be linked to aberrant aromatization of
adrenal androgens in estrogens, principally
E1.6 Feminization is often combined with
hypercortisolism, as we observed in our
patient.6 While AACs are for the most part spo-
radic, they can occur as part of various familial
tumor syndromes, such as MEN1, Li-Fraumeni
syndrome, Beckwith-Wiedemann syndrome,
and Carney complex.2,4 The familiar history of
our patient denoted the presence of well-
defined endocrine pathologies (MEN1 and
ACTH-producing pituitary adenoma). Adrenal
neoplasms are not commonly included in
MEN1; however, non-functioning macronodu-
lar hyperplasia is observed in up to 40% of
patients with MEN1 and, even rarely, ACCs can
occur.4 As a consequence, we investigated the
existence of MEN1 syndrome in our patient,
but the laboratory and imaging studies pre-
Article
Figure 1. Computed tomographic scan of
the abdomen revealed a large tumor of the
left adrenal (25 cm in its maximum diame-
ter) with colliquative areas, occupying
almost entirely the hemiabdomen. 
Figure 2. The adrenal mass measured
25×17 cm, and appeared encapsulated, yel-
lowish with extensive areas of necrosis and
mucoid degeneration, encompassing the
left kidney (black arrow). 
Figure 3. Histological examination with standard hematoxylin and eosin showing a pro-
liferation of large epithelial cells and pleomorphic oxyphil nuclei (A, 200×; B, 400×),
with large areas of necrosis and endovascular embolization (C, 100×; D, 200×).
Immunohistochemistry showing strong positivity for Melan-A and Synaptophysin in the
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vented us from confirming this hypothesis.  
In the described case, invasion of surround-
ing organs and distant metastases defined the
neoplasm as a carcinoma. However, differenti-
ation between benign tumors (adenomas) of
the adrenal cortex and ACCs is not always sim-
ple to achieve.3 The likelihood of being malig-
nant is very high for adrenal tumors producing
sex hormones; in particular, feminization is
quite consistent with malignancy more often
than virilization.5,8,9 As for the histological cri-
teria, the model proposed by Weiss in 1984 still
remains the most accurate and the one that
best correlates with the prognosis of ACCs.10
This model includes nine histological features
distinguishing benign from malignant tumors.
In our patient, 8 out of nine Weiss criteria
were satisfied.
ACCs are notoriously aggressive tumors
associated with poor prognosis. One cause for
this finding is certainly the fact that many
ACCs are detected at advanced stage. Preferred
sites of metastatic spread are liver, lungs, and
lymph nodes.
According to the literature, only 25-30% of
patients present with stage I-II (disease con-
fined to the adrenal), whereas about 70% pres-
ent with stage III-IV (disease extending
beyond the adrenal).2 The two most important
prognostic factors have been identified in
stage at diagnosis and surgical radicality,
though age, mitotic count, and Ki67 expres-
sion have also been considered.3,9,11,12
Historically, overall 5-year survival rates in
patients with ACCs range between15% and
20%. In a study from the Memorial Sloan
Kettering Cancer Center, patients with stage I-
II disease and with III-IV disease had 5-year
survival of 60% and 10%, respectively.13
Complete surgical resection is the only poten-
tially curative treatment, and nowadays
remains the mainstay in the treatment of
localized ACCs (stage I-III), even in patients
with extension to adjacent organs and positive
local lymph nodes. Five-year survival after sur-
gical resection is approximately 40%.12 Even
patients who undergo radical surgery bear
high risk (about 80%) of local relapse and
metastases, which typically occur within 2
years.2 When surgical removal is not achieved
with radical intent, the prognosis is very poor
(median survival <1 year). 
Although the use of laparoscopic adrenalec-
tomy for malignant AACs has been reported to
be safe by some authors, there is a common
agreement that open surgery should be pre-
ferred in this setting.14,15
Our patient had stage IV disease because of
distant metastases (lungs and liver) and inva-
sion of adjacent tissues.
In stage IV disease, chemotherapy or pallia-
tive cures have been the common options.3
Surgical resection of metastatic ACC remains
controversial, although surgery may have a
role in metastatic ACCs providing that greater
than 90% of the tumor and metastases can be
removed, according to the National
Comprehensive Cancer National guidelines.
In the case described herein, the manage-
ment decision was quite complex, as a result of
the patient’s young age, the presence of wide-
spread disease and the local extension of the
primary tumor. Following a multi-disciplinary
approach, we decided to operate on the patient
because of the local effects of tumor. Medical
treatments had failed to alleviate these symp-
toms. The intention was obviously not to cure
the patient with surgery, but to ameliorate his
quality of life, and thus obtain a good palliation
for mass effects and hormonal symptoms. To
note, he lived with an acceptable quality of life
for 12 months after the surgical removal of the
adrenal mass. We can reasonably speculate
that, in this case, surgery might have pro-
longed the overall patient survival.
Mitotane, alone or in combination with
other chemiotherapics has historically been
the main medicament used in the adjuvant
setting following radical surgery as well as in
metastatic disease. Its use is limited by signif-
icant, dose-dependent gastrointestinal and
neurologic toxicity; in our case the mitotane
therapy was quite well tolerated.
Survival rates from ACC have not substantial-
ly changed over the last 20 years, and systemic
treatment, to date, is unsatisfactory. 
The phase III FIRM-ACT trial comparing two
different regimens in metastatic ACCs (etopo-
side, doxorubicin, cisplatin, and mitotane ver-
sus streptozotocin and mitotane) showed no dif-
ference between the two regimens in terms of
overall survival (14.8 vs 12.0 months; P=0.07).16
Individualized therapies based on genomic
and expression profiling of ACCs represent
other promising perspectives.2,14 As knowledge
of the molecular mechanisms of ACCs contin-
ues to improve, it is likely that targeted thera-
pies will improve survival outcomes in the near
future. Numerous trials are investigating tar-
geted agents such as epidermal growth factor
inhibitors, antiangiogenic agents, tyrosine
kinase inhibitors, IGF-1 inhibitors, and fibrob-
last growth factor receptor inhibitors.2,14
In our opinion, this report contains two
principal points of interest. First, we empha-
size the fact that feminizing ACC should be
taken into account as a possible diagnosis in
patients presenting with gynecomastia, espe-
cially when the common causes for this disor-
der have been ruled out. Second, surgery may
have a role even in patients with functioning
ACCs at stage IV, with the aim of improving
quality of life by relieving symptoms of hor-
monal excess and mass effects. 
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